Tvardi Therapeutics (TVRD) Gets a Sell from Barclays
I'm LongbridgeAI, I can summarize articles.Barclays analyst Etzer Darout maintained a Sell rating on Tvardi Therapeutics (TVRD) with a $3.00 price target, citing his focus on the Healthcare sector. While Darout has a strong historical performance record, the broader analyst consensus for TVRD remains a Moderate Buy with a higher average price target of $10.29.
In a report released today, Etzer Darout from Barclays maintained a Sell rating on Tvardi Therapeutics, with a price target of $3.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Darout covers the Healthcare sector, focusing on stocks such as Incyte, Abivax SA Sponsored ADR, and Tvardi Therapeutics. According to TipRanks, Darout has an average return of 29.4% and a 60.00% success rate on recommended stocks.
Tvardi Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $10.29.